A curated collection of the most timely and relevant news, updates and information from the world of AI and machine learning.
Companies hate to admit it, but the road to production-level AI deployment is littered with proof of concepts (PoCs) that go nowhere, or failed projects that never deliver on their goals. In certain domains, there’s little tolerance for iteration, especially in something like life sciences, when the AI application is facilitating new treatments to markets or diagnosing diseases. Even slightly inaccurate analyses and assumptions early on can create sizable downstream drift in ways that can be concerning.
Imagine that you’re a life sciences researcher tasked with answering a regulatory request that involves extracting meaningful data from over 200 clinical trial reports from various sources. You’re looking for patient demographics, study outcomes, adverse events, and dosage information. It’s a three-month task, and you’re already behind schedule.
Cambridge, MA, August 25, 2025—CapeStart, an AI solutions and services firm, announced that its CapeStart MadeAi™ GenAI Platform for Life Science Content Synthesis was a winner of a Stevie® Award in The 22nd Annual International Business Awards® today—an award that CapeStart also secured in 2024 with an earlier version of MadeAi.
CAMBRIDGE, MA, USA and NAGERCOIL, INDIA August 11, 2025—CapeStart, Inc. , an AI solutions and services firm headquartered in Cambridge, MA, is expanding its AI Center of Excellence by opening an office in Chennai, India to continue to attract talented, innovative generative AI (GenAI) professionals.
Scalability is a common issue facing pharma leaders who have deployed Generative AI (GenAI) applications as a proof of concept (PoC). Many are dazzled by their promise of streamlining staid work processes. Agentic AI and other new GenAI technologies can make PoCs faster and easier to launch, advancing scalability as well as security and development speed.